Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine Nasal Spray in Korean Participants With Treatment-Resistant Depression
NCT07053345Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Started Jun 2025; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07053345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053345.